TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7944696

Group type: EXPERIMENTAL
Intervention: Heparin-coated bypass circuits with an uncoated cardiotomy reservoir
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard uncoated bypass circuits
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heparin-coated bypass circuits
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 3060281

Group type: EXPERIMENTAL
Intervention: Postocclusive reactive circulatory hyperaemia (PORCH) test
Number of subjects: 144

Group type: COMPARATOR
Intervention: Allen's test
Number of subjects: 144
Study: 30479531

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT) - high-intensity intermittent training plus strength training, performed twice weekly for 12 weeks.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Strength Training (ST) - strength training sessions only, performed twice weekly for 12 weeks.
Number of subjects: 19
Study: 28578652

Group type: EXPERIMENTAL
Intervention: CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: CROSS protocol
Number of subjects: 594

Group type: COMPARATOR
Intervention: Standard perioperative chemotherapy regimen (not explicitly detailed in the abstract)
Number of subjects: 594
Study: 26313454

Group type: EXPERIMENTAL
Intervention: NAP/ESO (naproxen 500 mg/esomeprazole 20 mg, twice daily)
Number of subjects: 1219

Group type: COMPARATOR
Intervention: CEL (celecoxib 200 mg, once daily)
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: RAPID3
Number of subjects: 1219
Study: 24144615

Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Psychoeducation and Supportive Therapy (PST)
Number of subjects: 239
Study: 21039402

Group type: EXPERIMENTAL
Intervention: UVB exposure with 6% skin area and 0.75 SED (7.5 mJ cm(‐2))
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: UVB exposure with 12% skin area and 0.75 SED (7.5 mJ cm(‐2))
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: UVB exposure with 0.75 SED (7.5 mJ cm(‐2))
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: UVB exposure with 1.5 SED (15 mJ cm(‐2))
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: UVB exposure with 3.0 SED (30 mJ cm(‐2))
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall increase in 25(OH)D after irradiation
Number of subjects: 92
Study: 18949961

Group type: EXPERIMENTAL
Intervention: Extended high-frequency (EHF) audiometry
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Conventional audiometry
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: EHF audiometry
Number of subjects: 139
Study: 16753313

Group type: EXPERIMENTAL
Intervention: Psychosocial stress test
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-stress condition
Number of subjects: 20
Study: 12698181

Group type: EXPERIMENTAL
Intervention: irinotecan 200 mg x m(‐2) on day 1 plus raltitrexed 3 mg x m(‐2) on day 2 (arm B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: raltitrexed 3 mg x m(‐2) on day 1 (arm A)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: irinotecan plus raltitrexed
Number of subjects: 38
Study: 10392322

Group type: EXPERIMENTAL
Intervention: Sibrafiban (oral administration, once or twice daily for up to 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibrafiban (once-daily dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibrafiban (twice-daily dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibrafiban (oral administration)
Number of subjects: 0
Study: 8694022

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g ethyl ester daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Olive oil (6 g ethyl ester daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Safflower oil (6 g ethyl ester daily)
Number of subjects: 25
Study: 1687248

Group type: EXPERIMENTAL
Intervention: Cholecystectomy with removal of the whole cystic duct
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 65
Study: 6682293

Group type: EXPERIMENTAL
Intervention: Direct laser photocoagulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Indirect laser photocoagulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Direct photocoagulation
Number of subjects: 42
Study: 31735408

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intermittent Aerobic Training (IAT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 87
Study: 30290808

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 317
Study: 27746565

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 10mg ephedrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crystalloid preloading with ringer lactate 15 mL.kg‐1
Number of subjects: 100
Study: 24679996

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21
Study: 22397919

Group type: EXPERIMENTAL
Intervention: Mannheim Multicomponent Stress Test (MMST)
Number of subjects: 110
Study: 20977501

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 19

Group type: COMPARATOR
Intervention: CD4(+) CD25(+) T cell depletion
Number of subjects: 19

Group type: COMPARATOR
Intervention: BCG vaccination at 2nd month of life
Number of subjects: 19
Study: 18179661

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 0
Study: 15731987

Group type: EXPERIMENTAL
Intervention: Permethrin (1% creme rinse)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No exposure to known teratogenic drugs (control group)
Number of subjects: 147
Study: 12637338

Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin-antioxidant vitamins
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 10944479

Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg daily) for 26 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lutein (15 mg daily) for 26 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 26 days
Number of subjects: 0
Study: 8814423

Group type: EXPERIMENTAL
Intervention: Heart rate variability during sleep in patients with relapsing-remitting multiple sclerosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Responses to autonomic tests
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Magnetic resonance lesions correlation with cardiovascular sleep indexes
Number of subjects: 20
Study: 1392793

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily for 12 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 4019949

Group type: EXPERIMENTAL
Intervention: Metaproterenol (650 micrograms per puff, 2 puffs)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31394155

Group type: EXPERIMENTAL
Intervention: Benign EEG
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Malignant EEG
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Highly malignant EEG
Number of subjects: 161

Group type: COMPARATOR
Intervention: SSEP
Number of subjects: 161
Study: 29984830

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, thalidomide and dexamethasone (CTD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attenuated CTD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 26231819

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) delivered via videoconference (VTC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) delivered in person (IP)
Number of subjects: 0
Study: 25264948

Group type: EXPERIMENTAL
Intervention: Low-dose insulin (0.05 U/kg per hour)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-dose insulin (0.1 U/kg per hour)
Number of subjects: 50
Study: 23372145

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (MIE; 50% Vo2peak for 60 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isoenergetic high-intensity exercise (HIE; alternating 2 min at 25% and 2 min at 90% Vo2peak)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isoenergetic high-intensity exercise (HIE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (MIE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 6
Study: 20801010

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18077067

Group type: EXPERIMENTAL
Intervention: Automatic imitation of intransitive actions (hand opening and closing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions with spatial compatibility variations
Number of subjects: 0
Study: 16177446

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (5 pmol/min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BQ-788 (1 nmol/min)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mean plasma endothelin-1 levels
Number of subjects: 39
Study: 12943027

Group type: EXPERIMENTAL
Intervention: Poor change in dysfunctional attitudes
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Poor change in extreme thinking
Number of subjects: 121
Study: 10664826

Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) 50 micrograms intravenously
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study: 8863759

Group type: EXPERIMENTAL
Intervention: Running in water with a flotation device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bicycle ergometry
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both water running and bicycle ergometry
Number of subjects: 8
Study: 1355791

Group type: EXPERIMENTAL
Intervention: Ronactolol 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ronactolol 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ronactolol 120 mg
Number of subjects: 0
Study: 3899672

Group type: EXPERIMENTAL
Intervention: Prazosin 4 mg/day for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alphamethyldopa 250-750 mg/day for 6 weeks
Number of subjects: 20
Study: 31145214

Group type: EXPERIMENTAL
Intervention: Naldemedine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29425280

Group type: EXPERIMENTAL
Intervention: Early childhood stunting
Number of subjects: 2193

Group type: EXPERIMENTAL
Intervention: Early childhood underweight
Number of subjects: 2193

Group type: EXPERIMENTAL
Intervention: Early childhood wasting by BMIAZ
Number of subjects: 2193

Group type: EXPERIMENTAL
Intervention: Early childhood wasting by MUACAZ
Number of subjects: 2193
Study: 26879684

Group type: EXPERIMENTAL
Intervention: Counterweight-Plus weight management programme (12-20 weeks low calorie diet replacement, food reintroduction, and long-term weight loss maintenance)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual guideline-based care
Number of subjects: 280
Study: 25225424

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 to 4), granisetron (2 mg orally on days 1 to 4), and dexamethasone (4 mg orally on day 1 and 2 mg orally on days 2 to 3)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo, granisetron (2 mg orally on days 1 to 4), and dexamethasone (8 mg orally on day 1 and 4 mg orally on days 2 to 3)
Number of subjects: 362
Study: 22287757

Group type: EXPERIMENTAL
Intervention: Modified intermediate-dose cytarabine (mIDAC; Ara-C at a dose of 1.0 g/m(2) every 12 hours for 5 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-dose cytarabine (HDAC; Ara-C at a dose of 2.0 g/m(2) every 12 hours for 5 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-dose cytarabine (HDAC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Modified intermediate-dose cytarabine (mIDAC)
Number of subjects: 26
Study: 20465831

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing counseling approach
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 272
Study: 17660839

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 772

Group type: COMPARATOR
Intervention: Chemotherapy or autologous transplantation
Number of subjects: 772
Study: 18485530

Group type: EXPERIMENTAL
Intervention: Exercise condition (cycling exercise)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sedentary condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise condition
Number of subjects: 12
Study: 15468717

Group type: EXPERIMENTAL
Intervention: Activation of proinflammatory cytokines (TNF‐alpha, IL‐1alpha, IL‐2, IL‐6, IL‐8) and increased production of autoimmune complexes
Number of subjects: 47

Group type: COMPARATOR
Intervention: Basic therapy (angiotensin‐converting enzyme inhibitors, nitrates, diuretics, beta‐adrenoblockers; 27.6% received digoxin, disaggregatory agents)
Number of subjects: 47
Study: 11158499

Group type: EXPERIMENTAL
Intervention: DTaP booster
Number of subjects: 3522

Group type: COMPARATOR
Intervention: DT
Number of subjects: 3522
Study: 9233865

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily for 14 days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 21 days)
Number of subjects: 140
Study: 7956580

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 35
Study: 3606073

Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g immediately before vancomycin infusion, followed by 15 g at 2, 4, 6, and 8 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (equal volume of water)
Number of subjects: 6
Study: 31543378

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (statin therapy only)
Number of subjects: 100
Study: 31151480

Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback during treadmill training for 10 sessions over 5-6 weeks.
Number of subjects: 150

Group type: COMPARATOR
Intervention: No feedback during treadmill training for 10 sessions over 5-6 weeks (Control).
Number of subjects: 150
Study: 28178209

Group type: EXPERIMENTAL
Intervention: Berberol® K (Berberis aristata, Silybum marianum and monacolin K and KA), once a day during dinner for 3 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Berberol® K
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 25589237

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 20
Study: 24847155

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Everolimus-eluting, permanent polymer stent (PP-EES)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES) in Cohort JR
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Everolimus-eluting, permanent polymer stent (PP-EES) in Cohort JR
Number of subjects: 1123
Study: 23108814

Group type: EXPERIMENTAL
Intervention: Composite technique of endoscopic DCR (using cautery, cold instrumentation, and laser)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional endoscopic DCR
Number of subjects: 30
Study: 19735400

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 4 microg x kg(‐1) x min(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 6 microg x kg(‐1) x min(‐1)
Number of subjects: 20
Study: 16467562

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15801953

Group type: EXPERIMENTAL
Intervention: Good response group (GRG) with <25% blasts in bone marrow within the first 2 weeks of treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Poor response group (PRG) with >25% blasts in bone marrow
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Daunorubicin included in induction therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) in first complete remission (CR1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Previous MRC UKALL XI trial
Number of subjects: 42
Study: 11927701

Group type: EXPERIMENTAL
Intervention: Breastfeeding during heel lance
Number of subjects: 30
Study: 10235017

Group type: EXPERIMENTAL
Intervention: Surgical treatment for asymptomatic carotid artery disease with 60% or greater linear stenosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for symptomatic carotid artery disease with 50% or greater linear stenosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical recommendations
Number of subjects: 0
Study: 7638370

Group type: EXPERIMENTAL
Intervention: Histamine (H)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methacholine (M)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Histamine (H) and Methacholine (M)
Number of subjects: 23
Study: 2652176

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (no caffeine)
Number of subjects: 28
Study: 786667

Group type: EXPERIMENTAL
Intervention: 400 mg mephenoxalone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 900 mg paracetamol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of 400 mg mephenoxalone and 900 mg paracetamol
Number of subjects: 60
Study: 30246570

Group type: EXPERIMENTAL
Intervention: Art therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Narrative writing
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study: 30095173

Group type: EXPERIMENTAL
Intervention: NPT and PDT
Number of subjects: 24

Group type: COMPARATOR
Intervention: NPT only
Number of subjects: 24
Study: 25530068

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) plus oral morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PL) plus oral morphine
Number of subjects: 40
Study: 25781235

Group type: EXPERIMENTAL
Intervention: nateglinide (120 mg three times a day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: acarbose (50 mg three times a day)
Number of subjects: 85
Study: 23254437

Group type: EXPERIMENTAL
Intervention: Quinine plus primaquine (30 mg/day for 14 days)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus primaquine (30 mg/day for 14 days)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Artesunate (200 mg dose followed by 100 mg/day for 6 days)
Number of subjects: 116
Study: 22004768

Group type: EXPERIMENTAL
Intervention: CVD risk assessment/communication + behavior change program (tailored website and individual coaching)
Number of subjects: 314

Group type: COMPARATOR
Intervention: CVD risk assessment/communication
Number of subjects: 314
Study: 19250367

Group type: EXPERIMENTAL
Intervention: Evening induction (21:00 hours)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Morning induction (07:00 hours)
Number of subjects: 371
Study: 16458259

Group type: EXPERIMENTAL
Intervention: Testosterone (sublingual administration, single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 15123479

Group type: EXPERIMENTAL
Intervention: School-based care group (daily inhaled corticosteroids provided through the school)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: School-based care group
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: School-based care group (among children not exposed to secondhand smoke)
Number of subjects: 184
Study: 12141848

Group type: EXPERIMENTAL
Intervention: Interactive problem-based educational program (I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture-style educational program (L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (I and L)
Number of subjects: 0
Study: 9450159

Group type: EXPERIMENTAL
Intervention: Pivagabine 1800 mg/d for four weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 7949496

Group type: EXPERIMENTAL
Intervention: Intermittent bolus famotidine (50 mg/24 h, 25th‐75th percentiles = 40‐55 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous infusion famotidine (42 mg/24 h, 25th‐75th percentiles = 42‐52 mg)
Number of subjects: 20
Study: 3070612

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 21
Study: 31836930

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg at Weeks 0, 2, and 6 (induction phase)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg at Week 14 and every 8 weeks until Week 54 (maintenance phase)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 28510773

Group type: EXPERIMENTAL
Intervention: Video game play plus occlusion therapy (1 hour of video game play per day for the first month plus 6 hours of occlusion therapy per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Occlusion therapy alone (6 hours per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison between video game and occlusion group and occlusion only group
Number of subjects: 68
Study: 26077603

Group type: EXPERIMENTAL
Intervention: Nicotine patch (6 weeks)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Behavioral counseling (3 in-person sessions + 5 follow-up phone sessions)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo patch (6 weeks)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 269